View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
August 31, 2020updated 12 Jul 2022 11:39am

AstraZeneca’s Farxiga yields positive results in DAPA-CKD trial

AstraZeneca has reported positive data from the Phase III DAPA-CKD clinical trial of Farxiga (dapagliflozin) plus standard of care in chronic kidney disease (CKD) Stages 2-4 patients with increased urinary albumin excretion. 

AstraZeneca has reported positive data from the Phase III DAPA-CKD clinical trial of Farxiga (dapagliflozin) plus standard of care in chronic kidney disease (CKD) Stages 2-4 patients with increased urinary albumin excretion.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

When compared to placebo, the drug combination decreased the composite measure of worsening of renal function or risk of cardiovascular (CV) or renal death by 39%.

This data was observed to be consistent in patients with and without type-2 diabetes (T2D).

Farxiga is an oral, once-daily sodium-glucose co-transporter-2 (SGLT2) inhibitor. The international, multi-centre, randomised, double-blinded DAPA-CKD study assessed the efficacy of 10mg dose of the drug in a total of 4,304 patients across 21 countries.

The drug was given once daily on top of standard of care. The primary composite endpoint was worsening of renal function or risk of death.

Meanwhile, the secondary endpoints included the time to first occurrence of the renal composite, the composite of CV death or hospitalisation for heart failure (hHF), and death from any cause.

According to the trial results, the primary composite endpoint was ≥50% sustained reduction in estimated glomerular filtration rate (eGFR), onset of end-stage kidney disease (ESKD) and CV or renal death.

The absolute risk reduction (ARR) was reported to be 5.3% over the median time in study of 2.4 years. The trial also met all secondary endpoints, including significant decrease in death from any cause by 31%.

AstraZeneca BioPharmaceuticals R&D executive vice-president Mene Pangalos said: “With today’s results, Farxiga becomes the first SGLT2 inhibitor proven to significantly prolong the survival of patients with chronic kidney disease with and without type-2 diabetes and we look forward to sharing these data with regulatory authorities around the world.

“Farxiga is also the first medicine in its class to demonstrate benefit in treating both heart failure and chronic kidney disease in patients with and without type-2 diabetes, and reduce the risk of hospitalisation for heart failure and nephropathy in type-2 diabetes.”

The safety and tolerability of the drug were found to be consistent with its established safety profile. In the DAPA-CKD trial, patients treated with Farxiga reported fewer serious adverse events versus placebo.

Last week, AstraZeneca started dosing participants in a Phase I trial of monoclonal antibody (mAb) combination therapeutic AZD7442 to prevent and treat Covid-19.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena